InsiderTrades.com logo
Elon Musk’s Controversial New Project: “Apollo”
From InvestorPlace   |   Ad
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Click here to see the details because there's a lot of money at stake.
Anila Lingamneni net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Anila Lingamneni Biography and Net Worth

EVP of Haemonetics
Anila Lingamneni serves as Executive Vice President, Chief Technology Officer of the Company. Prior to joining the Company, Ms. Lingamneni previously served as Vice President, Renal R&D at Baxter International from February 2017 to March 2020, where she was responsible for the product portfolio delivering renal therapy solutions to dialysis patients, including devices, software, disposables and fluids. In this role, she led a globally distributed team of engineers and scientists to drive long-term product roadmap definition and therapy innovation and delivered critical product launches. From May 2013 to January 2017, Ms. Lingamneni also served as Vice President, Device Engineering at Baxter International, where she was responsible for all electromechanical devices and software applications for Baxter's medical device portfolio, including infusion systems, compounding systems, renal peritoneal and hemodialysis systems and acute renal therapy systems. Before joining Baxter, Ms. Lingamneni held several roles at General Electric Healthcare, including Chief Technology Officer of the X-Ray Diagnostic Imaging Business Unit. Ms. Lingamneni received a Bachelor of Science in Electrical and Electronics Engineering and a Master of Science in Mathematics from Birla Institute of Technology and Science in India, and she earned a Master of Science in Biomedical Engineering from Iowa State University.

What is Anila Lingamneni's net worth?

The estimated net worth of Anila Lingamneni is at least $1.23 million as of September 11th, 2023. Ms. Lingamneni owns 14,495 shares of Haemonetics stock worth more than $1,233,090 as of April 24th. This net worth approximation does not reflect any other investments that Ms. Lingamneni may own. Additionally, Ms. Lingamneni receives a salary of $1,090,000.00 as EVP at Haemonetics. Learn More about Anila Lingamneni's net worth.

How old is Anila Lingamneni?

Ms. Lingamneni is currently 56 years old. There are 6 older executives and no younger executives at Haemonetics. The oldest executive at Haemonetics is Mr. Josep Lluis Llorens, Executive Vice President of Global Manufacturing & Supply Chain, who is 62 years old. Learn More on Anila Lingamneni's age.

What is Anila Lingamneni's salary?

As the EVP of Haemonetics Co., Ms. Lingamneni earns $1,090,000.00 per year. There are 4 executives that earn more than Ms. Lingamneni. The highest earning executive at Haemonetics is Mr. Christopher A. Simon, CEO, President & Director, who commands a salary of $3,260,000.00 per year. Learn More on Anila Lingamneni's salary.

How do I contact Anila Lingamneni?

The corporate mailing address for Ms. Lingamneni and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Anila Lingamneni's contact information.

Has Anila Lingamneni been buying or selling shares of Haemonetics?

Anila Lingamneni has not been actively trading shares of Haemonetics during the last quarter. Most recently, Anila Lingamneni sold 2,305 shares of the business's stock in a transaction on Monday, September 11th. The shares were sold at an average price of $90.00, for a transaction totalling $207,450.00. Following the completion of the sale, the executive vice president now directly owns 14,495 shares of the company's stock, valued at $1,304,550. Learn More on Anila Lingamneni's trading history.

Who are Haemonetics' active insiders?

Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.

Are insiders buying or selling shares of Haemonetics?

During the last twelve months, insiders at the medical instruments supplier sold shares 4 times. They sold a total of 9,765 shares worth more than $863,630.52. The most recent insider tranaction occured on September, 12th when insider Stewart W Strong sold 228 shares worth more than $20,668.20. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.

Information on this page was last updated on 9/12/2023.

Anila Lingamneni Insider Trading History at Haemonetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/11/2023Sell2,305$90.00$207,450.0014,495View SEC Filing Icon  
5/30/2023Sell2,304$83.33$191,992.3216,800View SEC Filing Icon  
4/18/2022Sell189$56.55$10,687.9514,013View SEC Filing Icon  
5/19/2021Sell92$55.19$5,077.48View SEC Filing Icon  
4/16/2021Sell170$119.44$20,304.80View SEC Filing Icon  
See Full Table

Anila Lingamneni Buying and Selling Activity at Haemonetics

This chart shows Anila Lingamneni's buying and selling at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Haemonetics Company Overview

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $85.07
Low: $83.72
High: $85.75

50 Day Range

MA: $79.41
Low: $71.25
High: $87.05

2 Week Range

Now: $85.07
Low: $70.74
High: $95.26

Volume

231,275 shs

Average Volume

409,869 shs

Market Capitalization

$4.32 billion

P/E Ratio

34.58

Dividend Yield

N/A

Beta

0.36
Elon Musk’s Controversial New Project: “Apollo”
From InvestorPlace   |   Ad
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Click here to see the details because there's a lot of money at stake.